English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Today, autologous peripheral blood stem cell transplantation is considered as a substitute procedure for Autologous bone marrow transplantation. Treatment with G-CSF mobilizes CD34+ HSCs from bone marrow into peripheral blood and could be used as a marker for hematopoietic stem cells mobilization and subsequent apheresis. Methods: In this study, 60 patients that had hematologic malignancies were randomly categorized into the two groups and were given PD-grastim (group A: 20 μg/kg/day and B: 10 μg/kg/day) to evaluate 10 and 20 μg/kg/day of PD-grastim in stem cell mobilization for autologous transplantation. Their CD34+ cell enumeration was carried out when leukocyte count was reached above 10000 cells/μl. Apheresis was also carried out when CD34+ count was reached above 16 cells/μl. Results: Results of the groups A and B were statistically analyzed and there was a meaningful statistical difference in gender, drug taking day numbers, apheresis numbers, hospitalization period and injected blood units. Based on the results, group A patients had lesser hospitalization period and apheresis number than group B. Conclusion: This indicates that utilization of PD-grastim at dose 20 μl/kg/day has better therapeutic effects on the patients with hematologic malignancies and could be considered as the major therapeutic regimen.

advances in bioscience and clinical medicine

Comparison of 10 and 20 µg/Kg/day PD-Grastim in Stem Cell Mobilization in Patients with Hematologic Malignancies Candidate for Autologous Stem Cell Transplantation